Truly, the described clinical scenario1 had its origins in 1999 with the discovery and ongoing characterization of IL-18 binding protein (IL-18BP) by Novick et al.2 We are grateful for their correspondence detailing the salient properties of this molecule.3 Regrettably, our original article was unable to include such details due to space limitations and the need to provide sufficient detail on the clinical scenario presented. We obviously agree that this molecule is well suited to the task of therapeutically blocking IL-18.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qodmrq
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Blinatumomab is a bispecific T-cell engaging αCD19 antibody used in refractory or relapsed B-cell precursor acute lymphoblastic l...
-
About 540 million years ago a group of jellyfish washed ashore, died and fossilised – preserving evidence of the earliest example of an anim...
-
Purpose. To evaluate the diagnostic performance of the McMonnies questionnaire as a screening survey for dry eye in Chinese outpatients. Met...
-
To survive in its sand fly vector, the trypanosomatid protozoan parasite Leishmania first attaches to the midgut to avoid excretion, but eve...
-
Publication date: Available online 4 May 2017 Source: Journal of Dairy Science Author(s): V. Bonfatti, D. Vicario, A. Lugo, P. Carnier T...
-
The pursuit for clarity in diagnostic and treatment pathways for the complex, chronic condition of myalgic encephalomyelitis/chronic fatigue...
-
Background: Paget disease, Bowen disease, and malignant melanoma in situ are intraepidermal neoplasms, characterized by the presence of page...
-
IJMS, Vol. 18, Pages 1591: The Role of p16INK4a Pathway in Human Epidermal Stem Cell Self-Renewal, Aging and Cancer International Journal o...
-
With the explosion of healthcare information, there has been a tremendous amount of heterogeneous textual medical knowledge (TMK), which pla...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου